Brazil Establishes Faster Review Times for Some Clinical Trials

International Pharmaceutical Regulatory Monitor
A A
Brazilian regulator Anvisa has set a 90-day timeline for reviewing requests to conduct clinical trials that are also being done in other countries.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor